CO2020002170A2 - Anticuerpo anti-pacap - Google Patents

Anticuerpo anti-pacap

Info

Publication number
CO2020002170A2
CO2020002170A2 CONC2020/0002170A CO2020002170A CO2020002170A2 CO 2020002170 A2 CO2020002170 A2 CO 2020002170A2 CO 2020002170 A CO2020002170 A CO 2020002170A CO 2020002170 A2 CO2020002170 A2 CO 2020002170A2
Authority
CO
Colombia
Prior art keywords
antibodies
pacap antibody
migraine
compositions
treatment
Prior art date
Application number
CONC2020/0002170A
Other languages
English (en)
Inventor
Chetankumar Natvarlal Patel
Catherine Brautigam Beidler
Michael Parvin Johnson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2020002170A2 publication Critical patent/CO2020002170A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención ser refiere a anticuerpos contra el péptido activador de la adenilato ciclasa de la pituitaria, composiciones que comprenden tales anticuerpos y métodos para usar tales anticuerpos para el tratamiento del dolor incluyendo cefalea y/o migraña.
CONC2020/0002170A 2017-09-29 2020-02-27 Anticuerpo anti-pacap CO2020002170A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565278P 2017-09-29 2017-09-29
PCT/US2018/051898 WO2019067293A1 (en) 2017-09-29 2018-09-20 ANTI-PACAP ANTIBODIES

Publications (1)

Publication Number Publication Date
CO2020002170A2 true CO2020002170A2 (es) 2020-04-01

Family

ID=63794713

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0002170A CO2020002170A2 (es) 2017-09-29 2020-02-27 Anticuerpo anti-pacap

Country Status (25)

Country Link
US (3) US10519225B2 (es)
EP (1) EP3688035A1 (es)
JP (2) JP6952888B2 (es)
KR (1) KR102453573B1 (es)
CN (1) CN111164105B (es)
AR (1) AR113022A1 (es)
AU (1) AU2018341959B2 (es)
BR (1) BR112020003628A2 (es)
CA (1) CA3077304C (es)
CL (1) CL2020000705A1 (es)
CO (1) CO2020002170A2 (es)
CR (1) CR20200127A (es)
DO (1) DOP2020000060A (es)
EA (1) EA202090563A1 (es)
EC (1) ECSP20020293A (es)
IL (1) IL273529A (es)
JO (1) JOP20200069A1 (es)
MA (1) MA50654A (es)
MX (1) MX2020003563A (es)
NZ (1) NZ762312A (es)
PE (1) PE20201494A1 (es)
SG (1) SG11202002572YA (es)
TW (1) TWI701260B (es)
WO (1) WO2019067293A1 (es)
ZA (1) ZA202001058B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102648281B1 (ko) 2015-04-16 2024-03-14 하. 룬드벡 아크티에셀스카브 항-pacap 항체 및 그의 용도
TWI770020B (zh) 2016-04-15 2022-07-11 丹麥商Ｈ朗德貝克公司 人類化抗pacap 抗體及其用途
JP7551744B2 (ja) 2019-10-15 2024-09-17 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
WO2023051786A1 (zh) * 2021-09-30 2023-04-06 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522159B1 (en) 1990-03-17 2001-12-12 Takeda Chemical Industries, Ltd. Antibody to pituitary adenylate cyclase activating peptide-pacap, hybridoma and assay for pacap
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
FR2826747B1 (fr) 2001-07-02 2005-02-25 Gemplus Card Int Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce
EP1583550A2 (en) 2003-01-16 2005-10-12 D. Collen Research Foundation vzw Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia
US9939449B2 (en) * 2011-02-01 2018-04-10 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
JP6064861B2 (ja) 2013-03-05 2017-01-25 株式会社デンソー 熱電変換装置の製造方法
SG11201507416WA (en) * 2013-03-15 2015-10-29 Amgen Inc Human pac1 antibodies
EP3035950A4 (en) 2013-08-14 2017-05-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
KR102648281B1 (ko) 2015-04-16 2024-03-14 하. 룬드벡 아크티에셀스카브 항-pacap 항체 및 그의 용도
WO2017106578A1 (en) * 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
WO2017142961A1 (en) 2016-02-16 2017-08-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Treatment of traumatic brain injury or stroke

Also Published As

Publication number Publication date
JP6952888B2 (ja) 2021-10-27
US20190100579A1 (en) 2019-04-04
AU2018341959B2 (en) 2021-11-25
US20200131256A1 (en) 2020-04-30
US10519225B2 (en) 2019-12-31
CA3077304A1 (en) 2019-04-04
IL273529A (en) 2020-05-31
JOP20200069A1 (ar) 2020-04-28
EA202090563A1 (ru) 2020-06-24
KR102453573B1 (ko) 2022-10-12
CN111164105B (zh) 2023-07-04
WO2019067293A1 (en) 2019-04-04
NZ762312A (en) 2022-11-25
US10954292B2 (en) 2021-03-23
SG11202002572YA (en) 2020-04-29
CR20200127A (es) 2020-04-08
AU2018341959A1 (en) 2020-03-05
JP2022000049A (ja) 2022-01-04
CA3077304C (en) 2023-08-01
DOP2020000060A (es) 2020-08-15
US20210171616A1 (en) 2021-06-10
KR20200040881A (ko) 2020-04-20
MA50654A (fr) 2020-08-05
TWI701260B (zh) 2020-08-11
JP2020535167A (ja) 2020-12-03
ZA202001058B (en) 2022-06-29
MX2020003563A (es) 2020-08-03
CL2020000705A1 (es) 2020-09-11
ECSP20020293A (es) 2020-06-30
EP3688035A1 (en) 2020-08-05
PE20201494A1 (es) 2020-12-29
TW201920280A (zh) 2019-06-01
JP7221352B2 (ja) 2023-02-13
BR112020003628A2 (pt) 2020-09-01
AR113022A1 (es) 2020-01-15
CN111164105A (zh) 2020-05-15

Similar Documents

Publication Publication Date Title
ECSP20020293A (es) Anticuerpo anti-pacap
SV2018005662A (es) Moduladores del receptor x farnesoide
CL2017000410A1 (es) Y-diquetonas para el tratamiento y la prevención de envejecimiento cutáneo y arrugas.
MX2023009483A (es) Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MX2017010544A (es) Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
EA202090457A1 (ru) Комбинированная терапия ласмидитаном и антагонистом cgrp для применения в лечении мигрени
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
EA201790655A1 (ru) Новые активаторы растворимой гуанилатциклазы и их применение
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
CL2021001256A1 (es) Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer (divisional sol 201801470)
CO2021004934A2 (es) Composiciones y métodos para tratar retinitis pigmentosa
SA519410324B1 (ar) صياغات رش إيبينيفرين
CL2020001846A1 (es) Anticuerpos pac1 y sus usos
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
EA201992883A1 (ru) АНТИТЕЛА К TrkB
EA201791498A1 (ru) Производные глюкагона
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
EA201690732A1 (ru) Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций
MX2018015431A (es) Composicion cosmetica anti-signos, uso de la composicion, metodo de tratamiento anti-signos y dispositivo aplicador.
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease